Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) (NCT07601295)
A Phase II, Randomized, Double-Blind, Safety and Efficacy Study of Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class II-IV pulmonary arterial hypertension (PAH).
Who can join: Review the eligibility criteria below.
Location: The University of Arizona / Banner University Medical Center — Tucson, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- The University of Arizona / Banner University Medical Center — Tucson, Arizona
- University of California, San Francisco — San Francisco, California
- Stanford University — Stanford, California
- University of Colorado (UCD) Anschutz — Aurora, Colorado
- Harvard University / Brigham and Women's Hospital — Boston, Massachusetts
- Duke University — Durham, North Carolina
- University of Pennsylvania — Philadelphia, Pennsylvania
- Brown University/Rhode Island Hospital — Providence, Rhode Island
- University of Texas Southwestern — Dallas, Texas
- University of Washington — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension (PAH)
- A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag — Columbus, Georgia
- Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept. — Tucson, Arizona
- Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) — Aurora, Colorado
- PAH Exercise Study — Seattle, Washington
- A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension — Stanford, California
Explore by condition: All Pulmonary Arterial Hypertension (PAH) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.